×
About 2,715 results

ALLMedicine™ Langerhans Cell Histiocytosis Center

Research & Reviews  991 results

Top Ten Oncocytic Head and Neck Lesions to Contemplate.
https://doi.org/10.1007/s12105-022-01520-y
Head and Neck Pathology; Bullock MJ, Jiang XS

Mar 18th, 2023 - Oncocytes are a component of many metaplastic and neoplastic lesions throughout the head and neck area, primarily originating in salivary/seromucinous glands and the thyroid gland. In addition, other lesions can contain cells that mimic oncocytes ...

Top Ten Lymphoproliferative Lesions Not to Miss When Evaluating Oral Ulcer Biopsies.
https://doi.org/10.1007/s12105-023-01532-2
Head and Neck Pathology; Hyrcza MD, Lindenmuth TR et. al.

Mar 18th, 2023 - Oral ulcers represent a full thickness loss of the mucosal epithelium leading to exposure of the submucosal connective tissue. These are common and usually self-limited lesions, although they may sometimes result from neoplasms, most commonly squa...

Myeloid cells from Langerhans cell histiocytosis patients exhibit increased vesicle tra...
https://doi.org/10.3324/haematol.2022.282638
Haematologica Hagey DW, Kvedaraite E et. al.

Mar 17th, 2023 - Langerhans cell histiocytosis (LCH) is a potentially life-threatening inflammatory myeloid neoplasia linked to paediatric neurodegeneration, whereby transformed LCH cells form agglomerated lesions in various organs. Although MAP-kinase pathway mut...

Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
https://clinicaltrials.gov/ct2/show/NCT04079179

Mar 10th, 2023 - Histiocytic disorders are diseases caused by misfunctioning or buildup of particular immune cells called histiocytes. Many histiocytic disorders (LCH, juvenile xanthogranuloma (JXG), Erdheim-Chester disease (ECD), and Rosai-Dorfman Disease (RDD)) ...

Primary diffuse Rosai-Dorfman disease in central airway: a case report and literature r...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9999564
BMC Pulmonary Medicine; Wu L, Zhang Y et. al.

Mar 10th, 2023 - Rosai-Dorfman disease (RDD) is a rare benign non-langerhans cell histiocytosis, mainly involving lymph nodes and skin. It is even rarer occurring only in central airway of lung and in diffuse form. Central airway RDD is similar to malignant tumor ...

see more →

Guidelines  1 results

The Mayo Clinic Histiocytosis Working Group Consensus Statement for the Diagnosis and E...
https://doi.org/10.1016/j.mayocp.2019.02.023
Mayo Clinic Proceedings; Goyal G, Young JR et. al.

Sep 2nd, 2019 - Histiocytic neoplasms, a rare and heterogeneous group of disorders, primarily include Erdheim-Chester disease, Langerhans cell histiocytosis, and Rosai-Dorfman disease. Due to their diverse clinical manifestations, the greatest challenge posed by ...

see more →

Clinicaltrials.gov  37 results

Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
https://clinicaltrials.gov/ct2/show/NCT04079179

Mar 10th, 2023 - Histiocytic disorders are diseases caused by misfunctioning or buildup of particular immune cells called histiocytes. Many histiocytic disorders (LCH, juvenile xanthogranuloma (JXG), Erdheim-Chester disease (ECD), and Rosai-Dorfman Disease (RDD)) ...

A Study With DAY101 as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
https://clinicaltrials.gov/ct2/show/NCT05287295

Mar 9th, 2023 - PRIMARY OBJECTIVE: I. To determine overall response rate (ORR) for children and young adults with relapsed or refractory Langerhans cell histiocytosis (LCH) treated with tovorafenib (DAY101) after 2 cycles. SECONDARY OBJECTIVES: I. To determine na...

International Rare Histiocytic Disorders Registry (IRHDR)
https://clinicaltrials.gov/ct2/show/NCT02285582

Dec 15th, 2022 - Histiocytoses are rare diseases caused by an excess of cells called Histiocytes, which can infiltrate the skin, bones, lungs, liver, spleen and the central nervous system. These disorders can range from localized involvement that resolves spontane...

Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders
https://clinicaltrials.gov/ct2/show/NCT02425904

Sep 29th, 2022 - This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational intervention, to learn whether the drug works in treating a specific disease, in this case, clofarabine to treat LCH. "Investig...

Inherited Genetic Susceptibility in Langerhans Cell Histiocytosis (LCH)
https://clinicaltrials.gov/ct2/show/NCT04100408

Sep 19th, 2022 - PRIMARY OBJECTIVES: I. To comprehensively characterize germline variants in SMAD6 and their association with LCH. II. To identify novel germline variants associated with LCH. III.To determine the role of genetic ancestry on LCH-related somatic mut...

see more →

News  56 results

Woman Seeks Answers After 3 Years of Painful Genital Ulcers
https://www.medpagetoday.com/dermatology/generaldermatology/102873

Jan 30th, 2023 - A woman in her late 40s presented with painful ulcers in her groin and armpits that hadn't healed in 3 years, an Indian group reported in JAMA Dermatology. The woman explained that when the sores first appeared, they were just itchy, oozing, reddi...

The High Cost of Cancer; Bone Fracture Risk in Survivors; MRI Gear Shortage
https://www.medpagetoday.com/hematologyoncology/othercancers/101580

Nov 4th, 2022 - The annual price of newly launched cancer drugs has increased 53% over the last 5 years, according to a report by U.S. Rep. Katie Porter (D-Calif.). (Reuters) A survey of large employers found that cancer has become the top driver of employer heal...

FDA Approves Cobimetinib for Histiocytic Neoplasms
https://www.onclive.com/view/fda-approves-cobimetinib-for-histiocytic-neoplasms

Nov 2nd, 2022 - The FDA has approved cobimetinib (Cotellic) for the treatment of adult patients with histiocytic neoplasms, which include Erdheim-Chester disease, Rosai-Dorfman disease, and Langerhans cell histiocytosis.1,2 The regulatory decision was based on d...

Treatment of Langerhans Cell Histiocytosis Clinical Practice Guidelines (NCCN, 2021)
https://www.medscape.com/viewarticle/963817

Dec 1st, 2021 - Guidelines for the treatment of Langerhans cell histiocytosis (LCH) were published in November 2021 by the National Comprehensive Cancer Network (NCCN) in Journal of the National Comprehensive Cancer Network.[1] Decisions regarding treatment of LC...

Yale Cancer Center Study Shows Cognitive Impairment for Survivors of Many Pediatric Cancers
https://www.onclive.com/view/yale-cancer-center-study-shows-cognitive-impairment-for-survivors-of-many-pediatric-cancers

Oct 6th, 2021 - In a new study led by Yale Cancer Center, researchers report many survivors of childhood cancers receive systemic therapies associated with cognitive effects and chronic health conditions that may impact long-term cognitive outcomes with downstrea...

see more →

Patient Education  1 results see all →